NEWS Recent News Recent News Recent Media Sep 8, 2015 – Selecta Biosciences Appoints Earl E. Sands, MD, as Chief Medical Officer Sep 8, 2015 – Selecta Announces $38 Million Series E Financing Jun 18, 2015 – Selecta Biosciences Synthetic Vaccine Particles Instrumental in Breakthrough Research on Mucosal Vaccines Jun 10, 2015 – Selecta Biosciences Initiates Phase 1 Clinical Program of SEL-212 May 13, 2015 – Selecta and Genethon Collaborate to Create Next Generation Gene Therapies Using Selecta’s Synthetic Vaccine Particle Platform May 13, 2015 – Sanofi Exercises Option on Second Therapeutic Program with Selecta Biosciences to Develop an Antigen-Specific Immunotherapy Based on Synthetic Vaccine Particle Technology Apr 6, 2015 – Selecta Biosciences to Webcast Presentation at Needham Annual Healthcare Conference Dec 23, 2014 – Selecta and Skolkovo Foundation Collaboration to Develop a Synthetic Vaccine Particle in the Field of Immuno-oncology Oct 15, 2014 – Selecta, JDRF and Sanofi Extend Collaboration to Develop a Synthetic Vaccine Particle Immunotherapy for Type 1 Diabetes Oct 15, 2014 – Selecta Announces More than $20 Million in Equity Funding Jun 17, 2014 – Selecta Accelerates Immune Tolerance Therapeutics and Announces New Product Candidate, SEL-212, for Refractory and Tophaceous Gout Jun 17, 2014 – Selecta Biosciences Enters Into Exclusive License Agreement with 3SBio to Develop Drug Candidate to Treat Gout Jun 17, 2014 – Selecta Biosciences to Accelerate Program for Novel Dual Action Vaccine for Malaria with support from the Bill & Melinda Gates Foundation Dec 9, 2013 – Selecta Biosciences Announces Successful Pre-clinical Study of SEL-201 As An Antigen-Specific Immune Tolerance Treatment for Patients Receiving Factor VIII Therapy Dec 9, 2013 – USPTO Allows First In a Series of Selecta Patents for Immune Tolerance Aug 27, 2013 – Selecta Biosciences Distinguished as World Economic Forum Technology Pioneer 2014 Nov 28, 2012 – Selecta and Sanofi Sign Global Collaboration Nov 28, 2012 – Selecta (RUS) LLC becomes RUSNANO’s first foreign portfolio company in the pharmaceutical sector to open a research center in Russia May 9, 2012 – Selecta Receives 2012 Edison Awards Gold Medal Nov 21, 2011 – Selecta Biosciences Initiates Phase 1 Clinical Study of SEL 068 Oct 27, 2011 – RUSNANO invests in Selecta Biosciences and BIND Biosciences Oct 27, 2011 – Selecta Announces 47 25 Million Financing Sep 6, 2011 – FierceBiotech Names Selecta Biosciences a 2011 Fierce 15 Biotech Aug 31, 2011 – Selecta Appoints Kishimoto Aug 31, 2011 – Selecta Biosciences Awarded Subcontract Jun 9, 2011 – Selecta Biosciences Appoints Peter Keller as Vice President of Business Development and Alliance Management Jun 9, 2011 – The Juvenile Diabetes Research Foundation and Selecta Biosciences Enter Research Collaboration for Vaccines for Type 1 Diabetes Aug 16, 2010 – Selecta Biosciences Appoints Werner Cautreels, Ph.D., as Company’s First CEO Aug 16, 2010 – Selecta Biosciences Receives $3 Million from NIH/NIDA to Develop Nicotine Vaccine for Smoking Cessation Apr 5, 2010 – Selecta Closes $15 Million Series C Financing Oct 29, 2009 – Selecta Co-Founder Named 2009 Mass High Tech All Star Feb 25, 2009 – Selecta Biosciences closes $15.1M Series B Financing Oct 8, 2008 – Selecta Biosciences Forms Distinguished Scientific Advisory Board Sep 4, 2008 – Selecta Biosciences Appoints Lloyd Johnston, Ph.D., as Vice President, Pharmaceutical Research and Development © 2015 Selecta Biosciences, Inc. | 480 Arsenal St., Building One, Watertown, MA 02472 | Phone: 617-923-1400 | Fax: 617-924-3454 | Email: info@selectabio.com Privacy Policy | Web site designed and developed by RainCastle Communications, Inc.